ADORA2A and Patent ductus arteriosus: Inhibition of CD73 was shown to suppress tumour growth in syngeneic mouse models37–39, and in fact, a first phase I/IB clinical trial investigating the preliminary activity of CD73 blocking antibody in combination with antibodies against anti PD-1 and/or adenosine A2A receptor in patients with advanced malignancies including PDA has been initiated in July 201840.